08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

CardioCel regulatory update

Admedus said CardioCel is now approved in Europe for use in the repair and reconstruction of heart valves. The product is also approved to treat congenital heart defects. CardioCel is a cardiovascular scaffold made from...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

CardioCel regulatory update

Health Canada approved Admedus' CardioCel to repair congenital heart deformities and more complex heart defects. CardioCel is a cardiovascular scaffold made from bovine pericardium that uses the company's ADAPT tissue engineering process. CardioCel is available...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

CardioCel patch regulatory update

FDA granted 510(k) clearance for Admedus' CardioCel patch for pericardial closure and repair of cardiac and vascular defects. The implantable tissue patch made from bovine pericardium using the company's ADAPT Tissue Engineering Process has CE...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

CardioCel patch: Pilot trial started

Allied Healthcare said investigators began an Australian pilot trial to evaluate CardioCel patch in up to 40 patients ages 1-12 years. The company said it expects a decision by mid-year on CE Mark of CardioCel....
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

CardioCel patch: Phase II data

Allied Healthcare's Celxcel division reported follow-up data from 14 pediatric patients who were implanted with CardioCel patches in a Phase II trial showing that all patients were free of patch-related complications or adverse events at...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

bioMD, Allied Medical Ltd. deal

bioMD received greater than the necessary 90% approval from Allied shareholders for its compulsory acquisition of Allied in a stock deal bioMD said is worth about A$22 million ($23.2 million). Allied shareholders will receive 32...